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In the present work we report the presence of protein kinase CK2 in lipid raft preparations from rat
brain synaptosomes, obtained after detergent extraction and subsequent isolation of detergent-
resistant membranes using sucrose gradient ultracentrifugation. Moreover, the phosphorylation
of syntaxin-1 at Ser14, a speciﬁc CK2 target, has been detected in lipid rafts, as assessed by a phos-
pho-speciﬁc antibody. Treatment with DMAT, a speciﬁc CK2 inhibitor, results in a decrease of syn-
taxin-1 Ser14 phosphorylation in lipid rafts, while the glutamate release from synaptosomes is
enhanced. In conclusion, CK2 might control neurotransmitter release by acting on SNARE proteins
attached to cholesterol-enriched microdomains.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein kinase CK2 (also known as casein kinase II or casein ki-
nase 2) is a ubiquitously expressed pleiotropic serine or threonine
kinase essential for life in eukaryotes. In many organisms, protein
kinase CK2 is a heterotetramer composed of two catalytic a- or a0-
subunits and two regulatory b-subunits [1]. Protein kinase CK2 is
known to phosphorylate more than 300 different substrates, which
include many proteins involved in transcription, RNA processing
and translation, and a restricted number of them also exert a reg-
ulatory role on CK2 activity [2]. These regulatory effects seem to
vary depending on the form of the enzyme (either holoenzyme
or free catalytic subunit) and the particular protein substrate.
Moreover, CK2 activity towards protein substrates involved in spe-
ciﬁc functions might also be modulated by the targeting of the ki-
nase to speciﬁc subcellular compartments [3]. Detection of protein
kinase CK2 activity in plasma membrane preparations has been re-
ported by various authors [4 among others], and some membranechemical Societies. Published by E
uı´mica i Biologia Molecular,
erra 08193, Barcelona, Spain.proteins, such as CKIP-1 (CK2-Interacting Protein-1) [5], have been
identiﬁed as CK2 partners. In addition, CK2 has been recently iden-
tiﬁed as a novel component of the KSR1 (kinase suppressor of ras)
scaffolding complex found in the plasma membrane that facilitates
ERK cascade signaling [6].
Lipid rafts have been proposed to exist in cell membranes as re-
sult of the differential afﬁnity associations of some lipids, such as
cholesterol and sphingolipids [7]. These microdomains have been
shown to be resistant to solubilization with mild detergents and,
thus, can be isolated as detergent resistant membranes (DRM) by
density ultracentrifugation [8]. Proteins incorporated into lipid
rafts are often modiﬁed, carrying glycosylphosphatidylinositol
(GPI)-anchors, palmitoylation, myristoylation, or they are attached
through directly binding cholesterol [7] or by the interaction with
rafts constituents [9].
In the present work we show that CK2 is present in membrane
microdomains from rat brain nerve endings and that the pharma-
cological inhibition of CK2 results in enhancement of glutamate re-
lease and in impairment of the phosphorylation of a CK2-speciﬁc
site, such as Ser14 of DRM-attached syntaxin1 (Stx1). These results
indicate the potential involvement of CK2 in the control of neuro-
transmitter release and open the possibility to a new level of CK2
regulation by means of substrate segregation by membrane
association.lsevier B.V. All rights reserved.
Fig. 1. CK2 subunits are present in lipid rafts from nerve ending membranes.
Membranes from synaptosomal-enriched fraction were solubilized with 1% Triton
X-100 for 30 min at 4 C (A) or with 1% Brij 98 for 30 min at 37 C (B). Subsequently,
each treated sample was fractionated in a discontinuous sucrose gradient. Equal
volumes of the recovered fractions were separated by SDS–PAGE and transferred to
nitrocellulose for immunoblotting analysis with antibodies against the indicated
proteins. Flotillin-1 is used as a lipid rafts marker, while the transferrin receptor
(TfR) is used as a marker of soluble membranes. DRM are found in fractions 1 and 2
in the Triton X-100 extraction and in fractions 2–4 in the Brij 98 extraction,
corresponding to the top of the ultracentrifuge tube, while fractions 10–12
correspond to the soluble membranes (SM) in both detergents. This analysis was
repeated in three independent experiments with similar results. Representative
results are shown.
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2.1. Antibodies
Antibody against transferrin receptor (clone H68.4) was from
Zymed Laboratories (San Francisco, CA, USA) and anti-Thy-1 (clone
OX7) was a gift from Dr. G. Schiavo (Cancer Research UK; London,
UK). Anti-GAP-43 and anti-syntaxin 1a/b (HPC-1) were from Sigma
(St. Louis, USA), while anti-phosphoSer14-syntaxin1a was from
Abcam (Cambridge, UK), anti-SNAP25 (SMI81) from Stenberger-
Meyer (Jarretsville, MD, USA), and anti-Flotillin-1 was from BD-
Transduction Laboratories (San Jose, CA, USA). Antibodies against
CK2a (clone H286), against CK2b (clone 6D5), against KSR1 (kinase
suppressor of Ras, C19) or against Raf-1 (C12) were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).
2.2. Isolation of detergent-resistant membranes
Crude synaptosomal fraction (P2) was prepared from Sprague–
Dawley as described previously [10], with slight modiﬁcations. Ali-
quots of synaptosomes were disrupted by sonication and mem-
branes precipitated by centrifugation 15 min at 190000g.
Protein concentration was determined according to the BCA proto-
col (Pierce; Rockford, IL, USA). Synaptosomal membranes (3 mg to-
tal protein) were solubilized with 2 ml of cold sodium buffer
(140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1 mM MgCl2, 1.2 mM
Na2HPO4, 20 mM Hepes/NaOH, and 10 mM glucose, pH 7.4) con-
taining 1% Triton X-100 (30 min at 4 C) or 1% Brij 98 (30 min at
37 C) by end-over-end mixing. Thereafter, the extracts were ad-
justed to 45% sucrose, and overlaid with 8 ml of 35% sucrose in so-
dium buffer and 2.5 ml of 5% sucrose in sodium buffer, inside an
ultracentrifugation tube. The DRM were isolated by ultracentrifu-
gation at 35,000 rpm, for 18 h, 4 C, using a SW41 rotor (Beckman
Instruments Inc.). Then the gradient was harvested in 12 fractions
of 1 ml. When indicated, synaptosomes were treated with methyl-
b-cyclodextrin at the indicated concentrations for 60 min, prior to
the detergent solubilization, in order to remove cholesterol from
the plasma membrane. Cholesterol was determined as in [10].
2.3. Electrophoresis and Western blot
Twenty-ﬁve micrograms of total cell extract protein was run on
SDS–polyacrylamide gel electrophoresis gels, transferred onto
polyvinylidene diﬂuoride membranes, and incubated with the cor-
responding antibodies. The membranes were developed with the
enhanced chemiluminescence West-pico method from Pierce.
2.4. Determination of CK2 activity
Protein kinase CK2 activity was assayed as described previously
[11]. Brieﬂy, 0.2 mM speciﬁc CK2 peptide (RRRAADSDDDDD) were
used, in the presence of 125 lM [c-32P] ATP and kinase buffer
(50 mM Tris/HCl, pH 7.5, 1.5 mM EGTA, 25 mM MgCI2, 10 mM so-
dium b-glycerolphosphate and 3 mM DTT) for 30 min at 30 C. The
samples were spotted on P81 papers, washed ﬁve times with 0.5%
orthophosphoric acid, once with acetone and air dried. Radioactiv-
ity was quantiﬁed in a scintillation counter.
2.5. Glutamate release
Glutamate release studies were performed as described previ-
ously [10]. Brieﬂy, aliquots of the P2 fraction were resuspended
in 500 ll of prewarmed sodium buffer and incubated at 37 C. Syn-
aptosomal suspensions were transferred to a cuvette containing
1.5 ml of the same buffer containing 1 mM NADP, 100 U glutamate
dehydrogenase (Sigma; Poole Dorset, UK), and 1.3 mM CaCl2 in athermoequilibrated chamber. Glutamate release was monitored
with the aid of a spectroﬂuorophotometer (Shimadzu RF5001PC).
Exocytosis was triggered by addition of KCl (50 mM ﬁnal concen-
tration). L-Glutamate (5 nmol) was added at the end of every deter-
mination, as an internal standard for calibration.
3. Results
3.1. Protein kinase CK2 is present in DRM from rat brain synaptosomes
Immunoblot detection of well established marker proteins
shows that TfR is totally solubilized with 1% Triton X-100, appear-
ing only in the fractions corresponding to soluble membranes,
while ﬂotilin-1 appears exclusively in DRM fractions (Fig. 1A),
demonstrating the correct extraction of DRM (assumed to corre-
spond to membrane rafts). The immuno detection of the CK2 sub-
units shows that CK2a and CK2b subunits are distributed in two
pools (Fig. 1A), one in the soluble membranes and the other in
DRM (approximately 50% of the total for both subunits, as assessed
by densitometry with the ImageJ software). Although Triton X-100
is the most commonly used detergent for isolation of rafts, some
new detergents with unique properties has been introduced, being
Brij 98 one of these [12]. The extraction of membrane microdo-
mains with this detergent can be carried at 37 C, avoiding the
non-speciﬁc clustering of lipidic components due to the low tem-
perature conditions used with Triton, that can lead to the mistaken
assignment of some proteins as raft residents [13]. The extraction
of DRM with 1% Brij 98 at 37 C shows that TfR is totally solubi-
lized, while ﬂotilin-1 appears exclusively in rafts fractions
416 C. Gil et al. / FEBS Letters 585 (2011) 414–420(Fig. 1B). The detection of the CK2 subunits shows similar results,
being CK2a and CK2b subunits distributed, also in this case, in
two pools, one in DRM (approximately 35% of the total for both
subunits) and the second in the non-DRM fractions (Fig. 1B).
CK2 activity in the gradients obtained with Triton X-100 or with
Brij 98 was determined by phosphorylation of a speciﬁc substrate
peptide (Fig. 2A, Triton, CK2 pept. or Brij 98, CK2 pept.), as well as
the endogen phosphorylation in absence of the substrate peptide
(Fig. 2A, Triton, endo or Brij 98, endo). The presence of CK2 activity
in the fractions corresponding to the DRM is evident in the treat-
ments with each detergent, being also present in the fractions cor-
responding to the soluble membranes (Fig. 2A). These results
totally agree with the immunoblot detection of CK2 subunits
shown in Fig. 1. In the solubilization with Triton X-100, a higher
content of unspeciﬁc endogenous phosphorylation is observed in
the rafts fraction than in the solubilization with Brij 98. This drove
us to use Brij 98 in the rest of the work. In order to conﬁrm the
presence of CK2 activity in the ultracentrifugation gradient after
Brij 98 treatment, phosphorylation of the substrate peptide in pres-
ence of 25 lM2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimid-
azole (DMAT) was performed, observing a clear decrease of peptide
phosphorylation (Fig. 2B).
3.2. Cholesterol depletion results in CK2 detachment from the
membrane
The removal of cholesterol from the plasma membrane by
methyl-b-cyclodextrin (MCD) disaggregates lipid rafts and allowsA
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Fig. 2. CK2 activity in DRM is inhibited by DMAT. (A) CK2 activity (as pmols of 32P
incorporated to substrate) in the gradient fractions after extraction with 1% Triton
X-100 (empty circles, endophosphorylation; ﬁlled circles, RADA peptide phosphor-
ylation) or with 1% Brij 98 (empty triangles, endophosphorylation; ﬁlled triangles,
RADA peptide phosphorylation). (B) CK2 activity on the RADA peptide in the
gradient fractions after extraction with 1% Brij 98 in the absence (empty circles) or
presence of DMAT 25 lM (ﬁlled triangles), a CK2 inhibitor. This analysis was
repeated in three independent experiments with similar results. Graphics show
mean ± SEM.its solubilization with detergents. Synaptosomal membranes were
treated with 35 mMMCD for 60 min at 37 C and subsequently sol-
ubilized with 1% Brij 98. After sucrose gradient ultracentrifugation,
the cholesterol content in each fraction was determined, showing
that MCD treatment totally eliminates the cholesterol (Fig. 3A).
The disruption of lipid rafts after 35 mM MCD treatment can also
be observed when the total protein content is determined, since
cholesterol removal dramatically decreases the protein peak from
rafts fractions and induces an increase in the protein content in
the solubilized membranes (Fig. 3B). The analysis by immunoblot
shows that 35 mM MCD allows the solubilization of the proteins
which were previously detected in DRM, since ﬂotillin-1, CK2a
and CK2b virtually disappear from DRM fractions, demonstrating
that the association of the studied proteins is cholesterol-depen-
dent. When the MCD concentration is raised to 50 mM, CK2 sub-
units are detached from the membrane, since no signal
corresponding to CK2a or CK2b appears in any fraction from the
gradient, while the marker proteins, i.e., ﬂotillin-1 and TfR, give
the same result than with 35 mM MCD (Fig. 3D). The determina-
tion of CK2 activity from the gradients resulting from the treat-
ments with 35 or 50 mM MCD totally conﬁrm the results
observed with the immunoblots (Fig. 3E). It is noteworthy that,
in the alternative treatments with both MCD concentrations, a gen-
eral loss of CK2 activity exists, being total in the case of 50 mM
MCD (Fig. 3E).
In order to conﬁrm the CK2 detachment from the membrane,
synaptosomal membranes were treated with increasing concentra-
tion of MCD (10, 35 or 50 mM) for 60 min. The membranes were
subsequently precipitated by centrifugation and the resulting
membrane-free medium taken for its analysis. MCD induces the re-
lease to the medium of approximately 30% of the total protein ini-
tially present in the membrane (Fig. 4A) and virtually depletes CK2
activity from the membrane, resulting the medium highly enriched
in CK2 activity (Fig. 4B). This observation is conﬁrmed by immuno-
blot analysis, being both CK2 subunits gradually detached from the
membrane with the increasing MCD concentrations. In contrast,
the treatment with increasing concentrations of MCD has no effect
on ﬂotillin-1 or either Stx1, two integral membrane proteins, or on
SNAP-25, a peripheral protein linked to the membrane by palmi-
toylation (Fig. 4C). In contrast, a high concentration of MCD such
as 50 mM has dramatic effects on Thy-1, a GPI-anchored protein,
and on GAP43, a membrane-attached protein via a dual palmitoy-
lation, both being totally removed from the membrane and re-
leased to the medium (Fig. 4C). Since it has been described that
CK2 is a component of the KSR1 scaffold complex that contributes
to Raf kinase activation [6], western blots for KSR1 and for Raf-1
were also performed, showing that both KSR and Raf-1 are also
gradually detached from the membrane with the increasing MCD
concentrations. Thus, these results imply that a pool that corre-
sponds to the 30% of the total protein can be completely detached
from synaptosomal membranes where they are initially bound.
This detachment is not general, being speciﬁc of certain proteins,
including CK2 subunits. Thus, peripheral membrane proteins seem
to be more sensible to the action of MCD than integral membrane
proteins. The immunodetection of KSR1 and of Raf-1 from the Brij
98-extracted DRM show that both proteins are present in DRM
fractions (Fig. 4D). Treatment with MCD 50 mM (see Fig. 3) de-
taches KSR1 and Raf-1 from membrane, as observed for CK2
subunits.
3.3. Pharmacological CK2 inhibition results in glutamate release
enhancement
Since syntaxin-1 (Stx1) is a CK2 substrate, a relevant protein in
nerve endings physiology and found in DRM from this cellular re-
gion [10,14], the presence of Ser14 phosphorylated-Stx1 was
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Fig. 3. CK2 binding to DRM is cholesterol-dependent. Synaptosomal membranes were treated, where indicated, with 35 mMMCD for 60 min prior to solubilization in 1% Brij
98 and fractionation on a discontinuous sucrose gradient. The cholesterol distribution in both treatments with or without 35 mM MCD (A) and the protein distribution (B)
along the gradients were determined. (C) The fractions were also analyzed by immunoblot with antibodies for ﬂotillin-1, transferrin receptor (TfR), CK2a and CK2b. (D)
Synaptosomal membranes were also treated with 50 MCD for 60 min prior to DRM extraction and subsequent immunoblots. (E) CK2 activity in the samples from the
gradients analyzed in C and D were determined and expressed as percentage of maximum. These analyses were repeated on two separate experiments. Graphics show
mean ± SEM.
C. Gil et al. / FEBS Letters 585 (2011) 414–420 417assessed by means of a phospho-speciﬁc antibody. The presence of
the phosphorylated Stx1 was found in DRM at a similar level than
the total Stx1 (Fig. 5A), corroborating the presence of physiologi-
cally active CK2 in DRM from nerve endings and also pointing to
the fact that the phosphorylation state of Stx1 does not affect its
localization in lipid rafts. Inhibition of CK2 with 25 lM DMAT re-
sults in a clear decrease in the Stx1 phosphorylation in DRM, but
was not apparent in the SM fractions (Fig. 5A). Since Stx1 is com-
ponent of the soluble N-ethylmaleimide sensitive factor attach-
ment protein receptor complex (SNARE complex), which is
essential for neurotransmitter release to occur, the effect of
DMAT-mediated CK2 inhibition in glutamate release from nerve
endings was assessed. Treatment of synaptosomes with 25 lM
DMAT increased approximately twofold the potassium-induced
glutamate release, indicating a negative regulation of CK2 on re-
lease (Fig. 5B).4. Discussion
Protein kinase CK2, one of the more conserved protein kinases
in evolution, is also one of the more challenging enzymes in the
cellular signaling ﬁeld, since it is ubiquitously expressed in nearly
every tissue of eukaryotes and it is also found in nearly every com-
partment of eukaryotic cells, even found as an ectokinase [15], but
any effective type of activity regulation has been described until
now. It is well known that CK2 activity is greater in all the brain
regions studied than in most of other tissues, and compelling evi-
dences demonstrate that CK2 phosphorylates an array of sub-
strates that have clear implications in neuritogenesis, synaptic
transmission, synaptic plasticity and neuronal development. Early
studies have shown a rapid increase of CK2 activity in hippocampal
Long Term Potentiation (LTP), a prevailing neurobiological model
for learning and memory [16]. In accordance to this observation,
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418 C. Gil et al. / FEBS Letters 585 (2011) 414–420it has been recently demonstrated, also in hippocampal neurons,
that Nerve Growth Factor activates CK2, then phosphorylating
and inhibiting the Phosphatase and Tensin Homologue Deleted
on Chromosome 10 (PTEN), leading to the inhibition of glycogen
synthase kinase-3b and to the stimulation of axonal growth [17].
It is noteworthy that PTEN contains a caveolin-1-binding motif
and can be recruited into lipid rafts from neurotumor cell lines
after C2-ceramide treatment [18]. Furthermore, it is known that
caveolin-2 (Cav-2) is phosphorylated in vivo by CK2 at two resi-
dues (Ser23 and Ser36) and that phosphorylation of Cav-2 is neces-
sary for its actions as a positive regulator of caveolin-1 duringcaveolae biogenesis [19]. Furthermore, detergent insolubility and
sucrose ﬂotation gradient experiments revealed that Ser23 phos-
phorylation of Cav-2 preferably occurs in DRM [20], pointing to a
possible interaction of CK2 with lipid rafts by means of, at least,
a substrate-driven mechanism. Pharmacological inhibition of CK2
also envisages an important role of CK2 in synaptic plasticity, since
pharmacological CK2 inhibition, affects LTP by selective modiﬁca-
tion in the location of synaptic NMDA (N-methyl-D-aspartate)
receptors [21].
Other CK2 membrane action that has been described is the one
that involves members of the KSR1 scaffolding complex. This
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Fig. 5. Protein kinase CK2 inhibition by DMAT impairs phosphorylation of Stx1 in
Ser14 and enhances glutamate release. (A) Synaptosomes were treated with DMAT
25 lM for 30 min, and subsequent extraction of DRM was performed. The levels of
Stx1 phosphorylation at Ser14 were assessed by western blot. Representative
results are shown from two separate experiments with similar results. (B)
Synaptosomes were treated with or without DMAT 25 lM for 30 min prior to
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induction of glutamate release in calcium-free conditions (unspeciﬁc). Graphs
shown are representative of three experiments, with similar results.
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upon signal activation, colocalizes MEK and ERK with the Raf fam-
ily kinases and also delivers the CK2 holoenzyme, which contrib-
utes to Raf activation [6]. The association of CK2 with rafts,
described in the present work, together with the known afﬁnity
of KSR for ceramide-rich membrane macro-domains [22] might
promote the interaction between CK2 and KSR. Since rafts play a
crucial role in regulating the phosphatidylinositol-3 kinase/Akt sig-
naling pathway [23], membrane rafts might also act as a meeting
platform allowing the convergence of CK2 and Akt signaling. Addi-
tional CK2 substrates that have been described as present in lipid
rafts in the system used in the present work [12] are synaptotag-
min I [24], VAMP/synaptobrevin [25] and Stx1 [26]. Stx1 is phos-
phorylated at Ser14 exclusively by CK2 [27]. The published data
suggest a role for CK2 and phospho-Stx1 in deﬁning speciﬁc subdo-
mains in the axonal plasma membrane that are segregated from
the synaptic active zones [28]. In spite of the fact that the func-
tional signiﬁcance and the stimuli that control the phosphorylation
of SNARE proteins remain unclear, several lines of evidence indi-
cate that this phosphorylation could have an important role in
the control of the calcium regulated exocytosis [29]. The data
shown in the present work are in support of this hypothesis. More-
over, Ser14 site in Stx1 is a critical modulator of mode 2/3 interac-
tion with Munc18-1, which controls vesicle immobilization at the
plasma membrane with the consequent control of exocytosis [30].In fact, deﬁcits in CK2-mediated phosphorylation of Stx1 have been
recently described as playing a role in the pathophysiology of
schizophrenia [31]. Moreover, a potential link between CK2 activ-
ity and inhibition of neurotransmission can be envisaged from the
reports on hippocampal neurons showing long-term depression by
the proBDNF-triggered activation of p75NTR [32] and the activation
of CK2 by the neurotrophin receptor p75NTR [17]. Thus, it is feasible
to hypothesize a mechanism in hippocampal neurons in which
neurotransmitter release can be impaired by CK2, after being acti-
vated in a presynaptic receptor dependent-manner, e.g., by a
p75NTR ligand. Thus, although most studies focus on lipid rafts at
the postsynaptic site, the present work suggests that lipid rafts
act also presynaptically to regulate neuronal function, as has been
suggested in previous works [10,14].
In conclusion, the association of CK2 to membrane rafts in neu-
ronal tissue described in the present work opens the possibility to
an additional control mechanism of this intriguing kinase, by
means of a putative raft-targeted mobilization towards protein
substrates or by control of the CK2 presence in the extracellular
medium, as well as supports the CK2-mediated modulation of exo-
cytotic events.
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